Anti-Reflux Devices Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Anti-Reflux Devices Market is segmented By Surgery Type (Invasive, Medigus ultrasonic Surgical Endostapler, Linx Reflux Managment, Non-invasive, Stretta, Endocinch Endolumminal Gastroplication, EsophyX, Endoscopic Plicator System, Plexiglas  poly-methyl-methacrylate (PMMA) microspheres), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others),  By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Anti-Reflux Devices Market Overview

The Anti-Reflux Devices Market Size was valued at US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029). 

 Anti-reflux devices are tend to target patients with GERD (Gastroesophageal reflux disease) and mild gastroesophageal junction (GEJ) defects.  These devices do not alter the anatomy of the esophagus, GEJ, or stomach so they  should not be considered as alternatives to surgical fundoplication for patients with significant anatomic abnormalities, including large hiatal or paraesophageal hernias. 

Anti-Reflux Devices Market Scope

To Know More: Download Sample

Anti-Reflux Devices Market Dynamics

The increasing prevalence of gastroesophageal reflux disease (GERD) will drive the market

Gastroesophageal reflux disease (GERD) is a digestive disorder that affects the ring of muscle between esophagus and stomach. This ring is called the lower esophageal sphincter(LES). And its symptom is generally heartburn. It is a common disease globally, increasing prevalence and consequently a more significant burden on the healthcare system. Traditionally, it is considered a disease of middle-aged and older people. Since risk factors for GERD affect a growing number of the adult population, concerns have been raised that increasingly younger people may develop GERD.

The surgery for GERD is known as antireflux surgery and it involves a procedure called fundoplication. The aim of fundoplication is to reinforce the LES to recreate the barrier that stops reflux from occurring. This is done by wrapping a portion of the stomach around the bottom of the esophagus to strengthen, augment, or recreate the LES valve. Antireflux operations in recent times are most often performed by using a minimally invasive surgical technique called laparoscopy. This technique utilizes a narrow tube-like camera and several long, thin operating instruments. The camera, instruments are inserted into the abdomen in the operating room through several tiny (less than 1 cm or ½ inch) incisions on the abdominal wall.GERD is one of the most common gastrointestinal disorders, with approximately 20% of adults in western culture. A systematic review by El-Serag et al. estimated the prevalence of GERD in the U.S. between 18.1% to 27.8%.

UCI Health esophageal disease experts now offer the LINX® Reflux Management System for people whose Non-invasive gastroesophageal reflux disease (GERD) cannot be controlled medically, including daily use of medications such as proton pump inhibitors (PPI).

The U.S. Food and Drug Administration (FDA) approved devices for the endoscopic treatment of GERD are:transoral incisionless fundoplication (TIF) (EsophyX device; EndoGastric Solutions, Redmond, Wash, USA), Medigus Ultrasonic Surgical Endostapler (MUSE) (Medigus Ltd, Omer, Israel), and Stretta.

Increasing investment and R&D in the treatment of gastroesophageal reflux disease (GERD) is expected to rise the market growth

Surgeons in the GERD and Gastrointestinal Surgery Program are the first in the area to offer a brand new, innovative device designed to treat gastroesophageal reflux disease (GERD) – the LINX® reflux management system. The LINX System is a small flexible band of interlinked titanium beads with magnetic cores designed to restore the body's natural barrier to reflux in patients with GERD.  Anti-reflux procedures offer a minimal invasive option for selected patients with GERD not controlled by PPIs, with randomized trials showing a variable degree of improvement in patient-oriented outcomes such as GERD-HRQL scores and the ability to decrease or discontinue the acid-suppressive medication.Reflux and belching after 270 degrees versus 360 degrees laparoscopic posterior fundoplication. To address this GERD treatment gap, minimal invasive  anti-reflux devices have been developed, allowing endoscopic fundoplication or lower esophageal sphincter (LES) compliance.

U.S. based EndoGastric Solutions® has received a significant round of funding from investors, including Vertex Growth Fund, to further accelerate commercialization efforts in support of the growing market demand for its Transoral Incisionless Fundoplication (TIF® 2.0) procedure performed with the EsophyX® device. The TIF 2.0 procedure is a minimal invasive endoscopic intervention performed with the EsophyX device, which enables anatomical correction of the gastroesophageal valve (GEV) without incisions or the complications typically associated with traditional anti-reflux surgical procedures. 

Recent data on gastro-oesophageal reflux disease management strategies show that the indirect costs of reflux disease are high and that inadequate treatment is associated with high out-patient costs for patients. As a result now, long-term management strategies focus on discontinuous therapy for some group of patients. On-demand therapy is particularly attractive for patients who have no mucosal disease because it is cost effective and convenient.

GERD can be annoying and even painful. But it is not a dangerous disease. For any GERD treatment to be worth trying, it needs to be very safe. For many people, especially those with few problems taking medicine, surgery is not a good choice.

But when fundoplication surgery is successful, it may end the need for long-term treatment with medicine. When deciding between surgery and treatment with medicine, weigh the cost, risks, and potential complications of the surgery against the cost and inconvenience of taking medicine.

LINX Reflux Management System reduces medical costs more than laparoscopic Nissen fundoplication (LNF), a more invasive anti-reflux surgery, and more than offsets the slightly higher cost of the procedure, according to a new study presented recently at the 2019 Annual Meeting of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES 2019). The research was partially funded by Ethicon, part of Johnson & Johnson Medical Devices Companies, in collaboration with Highmark Health's VITAL Innovation Platform, a test-and-learn environment for health innovations. The higher initial cost of a LINX procedure compared to a Nissen fundoplication is perceived as a drawback by insurers, making getting insurance approvals challenging.

COVID-19 Impact Analysis

The COVID-19 pandemic has impacted the healthcare systems globally. It has resulted in nationwide lockdown, impacting every industry. Likewise, the anti-reflux devices market is also affected because manufacturers shut down their business due to COVID-19 norms. So patients undergoing treatment lost access to services, and no surgeries had happened due to lockdown. In addition, dramatic reductions in E.D  visits prompted concern that individuals with severe conditions deferred treatment for fear of contracting COVID-19.

Anti-Reflux Devices Market Segment Analysis

Invasive surgery type segment dominated the market

In invasive surgery, The LINX Reflux Management System (Torax Medical, St. Paul, MN, USA) is designed to provide a permanent solution to GERD by augmenting the sphincter barrier standardized, reproducible laparoscopic procedure that does not alter gastric anatomy and is easily reversible. Two single-group trials confirmed that a magnetic device designed to augment the lower esophageal sphincter could be safely and effectively implanted using a standard laparoscopic approach. The device decreased esophageal acid exposure, improved reflux symptoms and quality of life, and allowed cessation of proton-pump inhibitors in the majority of patients. The magnetic sphincter augmentation (MSA) procedure (Linx Reflux Management System, Ethicon, Johnson & Johnson, Shoreview, Mn, USA) was developed as a less disruptive and more standardized and reproducible laparoscopic surgical option for the treatment of GERD. The MSA device is composed of a variable number of interlinked titanium beads with a magnetic core inside. This ring-like system produces a magnetic force that augments the LES. Such type advanced and consistent product advancement is expected to grow the market over the forecast period.

The hospital segment will dominate the market in the forecast period

In today's healthcare environment, surgical procedures may be performed in a variety of different settings. Hospitals have various support departments such as MRI suites and ICUs, and there have been concerns about their ability to handle significant problems during surgery.  On the other hand, they have more resources to manage complications. Patients are often transferred from a surgery center to the nearest hospital facility if complications arise during a procedure. As there are different type of surgeries for the treatment and  of GERD and require advanced technology, a hospital is the preferred segment.

Anti-Reflux Devices Market Geographical Analysis

North America region dominates the Anti-Reflux Devices Market

GERD has been recognized as a significant public health concern. Heartburn effects nearly two-thirds of U.S. adults at some point in their lives and accounts for 4 to 5 million physician office visits every year.

The prevalence of gastroesophageal reflux disease (GERD) has appreciably increased in last few decades in the United States, making it one of the most common Non-invasive diseases. It is estimated that up to 20%-25% of Americans experience symptoms of GERD weekly. Interestingly, most patients who visit their primary care doctor with typical GERD symptoms such as heartburn and regurgitation, never undergo formal diagnostic evaluation and are managed with non-surgical therapy such as proton pump inhibitors (PPI) long-term. According to the American Gastroenterological Association and the American College of Gastroenterology, patients with symptoms suggestive of GERD should undergo an 8-week empiric treatment regimen with a PPI.

Anti-Reflux Devices Market Competitive Landscape

The Anti-Reflux Devices Market is moderately competitive with the presence of local as well as global companies. Some prominent key players in this market are Olympus, Avantis Medical Systems, Mederi Therapeutics, Medigus, Torax Medical, EndoGastric Solutions, Merit Medical Systems, Inc., Medivators, Inc. Medsinglong Co Ltd., Guangzhou Medunion Technologies Co.ltd and Guangzhou Maya Medical Equipment.Co.ltd

Anti-Reflux Devices Market Key Companies to Watch

Torax Medical

Overview: Torax® Medical, Inc. is a privately held medical device company headquartered in St. Paul, Minnesota, that develops and markets products designed to treat sphincter disorders utilizing its technology platform, Magnetic Sphincter Augmentation (MSA). Torax Medical markets both the LINX® Reflux Management System for GERD treatment and the FENIX® Continence Restoration System for the treatment of Fecal Incontinence (F.I.).

Product Portfolio: The Company offers products that treat sphincter disorders utilizing its technology platform and is a  medical device company that manufactures and markets the LINX Reflux Management System for the surgical treatment of Gastroesophageal Reflux Disease (GERD).

Key Development: Johnson & Johnson's Ethicon unit has agreed to acquire Torax Medical, which markets devices to treat gastrointestinal conditions stemming from sphincter issues. In the deal, J&J will pick up a minimally invasive treatment for gastroesophageal reflux disease, the Linx Reflux Management system. A small, flexible band of magnetic titanium beads helps prevent reflux by stopping the lower esophageal sphincter from opening due to stomach pressure.

Why Purchase the Report?

• Visualize the composition of the anti-reflux devices market—segmentation by Surgery Surgery Type and End-user highlighting the key commercial assets and players.
• Identify commercial opportunities in Anti-Reflux Devices Market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of Anti-Reflux Devices Market - level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The Anti-Reflux Devices Market report would provide an access to an approx. 52 market data table, 42 figures and 200 pages. 

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers